Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.
Key Details
- 1Collaboration leverages ECOG-ACRIN's clinical trial data and Caris' molecular profiling and imaging AI platforms.
- 2Over 4,000 TAILORx trial patient cases used to train and validate new multimodal deep learning models.
- 3Models integrate histopathologic slide imaging, clinical, and expanded gene expression data.
- 4AI models outperformed established recurrence risk assessment methods, especially for late recurrence (after 5 years).
- 5Potential shown for a scalable, cost-effective diagnostic test based on routine histology and clinical data rather than solely on genomic assays.
- 6Results presented at the 2023 San Antonio Breast Cancer Symposium.
Why It Matters
The study demonstrates unprecedented large-scale integration of imaging, molecular, and clinical data for recurrence prognostication, charting a path toward more personalized and precise breast cancer management. Imaging AI's role in such multimodal frameworks signifies a promising advance for the development of new diagnostic tools in oncologic pathology.
Source
EurekAlert
Related News
•EurekAlert
AI Tool Predicts Risks for Cancer Patients After Heart Attack
A new AI-powered risk prediction model assists clinicians in treating cancer patients following a heart attack by combining oncology and cardiovascular data.
•EurekAlert
Large Language Models Rival Physicians in Complex Lung Cancer Decisions
A real-world study reveals that large language models (LLMs) can match or exceed human physicians' performance in challenging lung cancer case decision-making, especially for rare cases.
•EurekAlert
Intelligent Medicine Journal Rises in International Influence Rankings
Intelligent Medicine ranks 66th in China's top internationally influential journals, reflecting its impact in AI-driven clinical research.